| Literature DB >> 35697804 |
Megan Schwarz1,2, Denis Torre1,2, Daniel Lozano-Ojalvo3, Anthony T Tan4, Tommaso Tabaglio5, Slim Mzoughi1,2, Rodrigo Sanchez-Tarjuelo1,6, Nina Le Bert4, Joey Ming Er Lim4, Sandra Hatem1, Kevin Tuballes3, Carmen Camara7, Eduardo Lopez-Granados7, Estela Paz-Artal8,9,10, Rafael Correa-Rocha11, Alberto Ortiz12, Marcos Lopez-Hoyos13, Jose Portoles14, Isabel Cervera6, Maria Gonzalez-Perez6, Irene Bodega-Mayor6, Patricia Conde6, Jesús Oteo-Iglesias6,10, Alberto M Borobia15, Antonio J Carcas15, Jesús Frías15, Cristóbal Belda-Iniesta16, Jessica S Y Ho17, Kemuel Nunez1,2, Saboor Hekmaty1, Kevin Mohammed1, William M Marsiglia1, Juan Manuel Carreño17, Arvin C Dar1,2, Cecilia Berin18, Giuseppe Nicoletti19, Isabella Della Noce19, Lorenzo Colombo19, Cristina Lapucci20, Graziano Santoro20, Maurizio Ferrari21, Kai Nie3,22, Manishkumar Patel3,22, Vanessa Barcessat3, Sacha Gnjatic1,3,22, Jocelyn Harris3,22, Robert Sebra23,24,25,26, Miriam Merad3,22, Florian Krammer17, Seunghee Kim-Schulze3,22, Ivan Marazzi17, Antonio Bertoletti27, Jordi Ochando28,29,30, Ernesto Guccione31,32,33.
Abstract
Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based: qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-γ, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.Entities:
Year: 2022 PMID： 35697804 DOI： 10.1038/s41587-022-01347-6
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908